Royalty Pharma Secures Full Control of Evrysdi Royalty Stream With Remaining PTC Therapeutics Deal

2025-12-31 16:02:22

Royalty Pharma plc (RPRX) has finalized the acquisition of the last remaining royalty interest in Roche’s Evrysdi from PTC Therapeutics, establishing complete ownership of the tiered royalty payments tied to the blockbuster drug’s global sales performance.

Transaction Structure and Financial Terms

The deal encompasses a substantial upfront payment of $240 million, with an additional $60 million available through sales-based milestone achievements. This final transaction consolidates Royalty Pharma’s position as the sole recipient of Roche’s royalty obligations on worldwide Evrysdi net sales, eliminating any remaining shared interests.

Tiered Royalty Framework

The royalty structure grants Royalty Pharma escalating percentage payments based on sales tiers: 8% commission on revenues up to $500 million, 11% on the $500 million to $1 billion band, 14% on sales between $1 billion and $2 billion, and 16% on sales exceeding the $2 billion threshold. This multi-tiered approach aligns royalty compensation with market expansion.

Revenue Impact Timeline

Royalty Pharma will commence receiving the elevated royalty payments during the first quarter of 2026, reflecting Evrysdi sales generated throughout the final quarter of 2025. This timing positions the company to benefit from the drug’s continued market penetration and revenue growth trajectory.

Disclaimer: The perspectives presented herein represent the author’s viewpoint and may not align with official positions held by Nasdaq, Inc.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.